^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Fucaso (equecabtagene autoleucel)

    i
    Company:
    IASO BIO, Innovent Biologics
    Drug class:
    BCMA-targeted CAR-T immunotherapy
    Related drugs:
    Apply
    Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System (CARTinNS) (NCT04561557)
    Phase 1
    Tongji Hospital
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    09/22/2020
    Primary completion :
    02/22/2027
    Completion :
    05/31/2027
    CD8 • IL6 • CD4
    |
    cyclophosphamide • fludarabine IV • Fucaso (equecabtagene autoleucel)
    A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma (NCT05201118)
    Phase 1
    Chunrui Li
    Recruiting
    Last update posted :
    05/24/2022
    Initiation :
    01/01/2022
    Primary completion :
    12/31/2022
    Completion :
    12/31/2023
    IL6
    |
    Xpovio (selinexor) • Fucaso (equecabtagene autoleucel)
    A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2) (NCT05181501)
    Phase 1
    Nanjing IASO Biotherapeutics Co.,Ltd
    Not yet recruiting
    Last update posted :
    01/06/2022
    Initiation :
    04/01/2022
    Primary completion :
    04/01/2024
    Completion :
    04/01/2039
    IL6
    |
    Fucaso (equecabtagene autoleucel)